| Neratinib after trastuzumab-based adjuvant therapy in patients from Asia with early stage HER2-positive breast cancer | |
| Iwata Hiroji; Masuda Norikazu; Kim Sung-Bae; Inoue Kenichi; Rai Yoshiaki; Fujita Takashi; Chiu Joanne; Ohtani Shoichiro; Takahashi Masato; Miyaki Toshiko | |
| 2019 | |
| 卷号 | 15期号:21页码:2489-2501 |
| 关键词 | Asia HER2 early stage breast cancer efficacy extended adjuvant therapy neratinib safety tyrosine kinase inhibitor |
| ISSN号 | 1744-8301 |
| DOI | 10.2217/fon-2019-0143 |
| URL标识 | 查看原文 |
| 收录类别 | PUBMED |
| 内容类型 | 期刊论文 |
| URI标识 | http://www.corc.org.cn/handle/1471x/6340764 |
| 专题 | 中国医学科学院 北京协和医学院 |
| 推荐引用方式 GB/T 7714 | Iwata Hiroji,Masuda Norikazu,Kim Sung-Bae,et al. Neratinib after trastuzumab-based adjuvant therapy in patients from Asia with early stage HER2-positive breast cancer[J],2019,15(21):2489-2501. |
| APA | Iwata Hiroji.,Masuda Norikazu.,Kim Sung-Bae.,Inoue Kenichi.,Rai Yoshiaki.,...&Chan Arlene.(2019).Neratinib after trastuzumab-based adjuvant therapy in patients from Asia with early stage HER2-positive breast cancer.,15(21),2489-2501. |
| MLA | Iwata Hiroji,et al."Neratinib after trastuzumab-based adjuvant therapy in patients from Asia with early stage HER2-positive breast cancer".15.21(2019):2489-2501. |
| 个性服务 |
| 查看访问统计 |
| 相关权益政策 |
| 暂无数据 |
| 收藏/分享 |
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
修改评论